Aurobindo Pharmaceuticals Follow Verify

Aurobindo has robust product portfolio spread over major product areas encompassing CVS, CNS, Anti-Retroviral, Antibiotics, Gastroenterologicals, Anti-Diabetics and Anti-Allergic with approved manufacturing facilities by USFDA, UKMHRA, WHO, MCC-SA, ANVISA-Brazil for both APIs & Formulations

http://www.aurobindo.com/
Type	Public / Private
Industry	Pharmaceutical
Founded	1986
Headquarters	Aurobindo Pharma Limited Water Mark Building, Plot No. 11, Survey no.9, Kondapur, Hitech City, Hyderabad - 500 084

History

Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.

Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.

Started from Single unit manufacturing devision now Aurobindo's nine units for APIs / intermediates and seven units for formulations are designed to meet the requirements of both advanced as well as emerging market opportunities.

A well integrated pharma company, Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations. the customers include premium multi-national companies.. With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs from India.

Business units

1- API (active pharmaceutical ingredient)-Aurobindo Antibiotics Limited, Silicon life sciences private limited

2- Formulation.-APL Healthcare Limited,Eugia Pharma Specialities Limited,Hyacinths Pharma Private Limited

3- Parenterals -Curepro Parenterals Limited

4- Peptides-Auro Peptides Limited

5- Nutraceutical- Based in USA

6- Bio catalysts-AuroZymes Limited

7- Biotechnology-Tergene Biotech Private Limited

8.- ARVs and HIVs-

8- Research and Development-APL Research Centre Limited

Manufacturing capabilities

Aurobindo has retained the same drive for growth that marked its early days. Starting off with a small SSP manufacturing unit in 1988, Aurobindo has grown to become the market leader in SSPs, non penicillins, cephalosporins, and non cephalosporins. In the global market, we believe in retaining our leadership in SSPs, cephalosporins, new anti-infectives and lifestyle disease drugs.

OUR KEY FORMULATION FACILITIES (6 IN INDIA, 1 EACH IN THE US AND BRAZIL):

UNIT 3 An exclusive multi-product oral dosage form facility spread over 40,469 sq. meters for non cephalosporins and non beta-lactams Spread over 40,469 sq. meters.
UNIT 4 A dedicated manufacturing facility for generic sterile injectables (lyophilized and powder injections, prefilled syringes), opthalmics and low volume parenterals. The facility is spread over 33 acres with a built-up area of 20,000 square. meters.
UNIT 6 A dedicated facility spread over 58,060 square. meters for manufacturing oral and sterile cephalosporin formulations. Spread over 58,060 sq. meters.
UNIT 7 An ultra modern unit based on the suite manufacturing concept for huge capacities. Manufactures non penicillins, non cephalosporins & ARVs
UNIT 12 A dedicated facility spread over 15,228 square. meters.for manufacturing oral and sterile beta-lactam formulations. Spread over 15,228 sq. meters.
AURONEXT To produce sterile penem formulations. Also manufactures sterile APIs
AUROLIFE (LOCATED IN THE US) A 100,000 square feet state-of-the-art USFDA approved cGMP compliant manufacturing facility located in New Jersey Manufactures non-pencillins and non-cephalosporin products
BRAZIL Have an exclusive manufacturing facility for SSPs, which caters to the requirements of Latin America

Accreditation

The eight formulation manufacturing facilities located in India, USA and Brazil. Our facilities have received accreditations from the following regulatory bodies:

• US FDA (United States Food and Drug Administration)
• UK's MHRA (United Kingdom's Medicines and Health products Regulatory Agency)
• TGA Australia (Therapeutic Goods Administration)
• MCC South Africa (Medicines Control Council)
• ANVISA Brazil (National Health Surveillance Agency)
• Health Canada and
• GCC DR (Gulf Central Committee for Drug Registration) 

Top 5 Recent Tweets

Date	Author	Comment
April 09, 2023	happyinvestings	Nifty Pharma Index Sun Pharmaceutical Dr. Reddys Laboratories Cipla Divis Laboratories Lupin Alkem Laboratories… https://t.co/YMYbHblqHn

Top 5 Recent News Headlines

1. Aurobindo Pharma soars 6% after co outlines future plans The company outlined a presentation for investors, which highlighted the company’s plans to increase collaboration across global customer businesshttp://www.moneycontrol.com/news/business/stocks-business/aurobindo-pharma-soars-6-after-co-outlines-future-plans-2295041.html
2. Aurobindo Pharma up 12% as company expects pricing pressure to ease in FY2018 http://www.sify.com/finance/aurobindo-pharma-up-12-as-company-expects-pricing-pressure-to-ease-in-fy2018-news-equity-rf4plIejehicd.html
3. Aurobindo Pharma Q4 net profit declines 4%http://www.thehindu.com/business/aurobindo-pharma-q4-net-profit-declines-4/article18661563.ece
4. Aurobindo Pharma up 11% post Q4 nos; co sees better FY18, less US pricing pressure The healthcare company, in its conference call, said price erosion in the US is likely to continue and that may be 7-8 percent. This is far less than its peers that expect in double digits. http://www.moneycontrol.com/news/business/stocks-business/aurobindo-pharma-spikes-over-6-on-better-fy18-outlook-sees-less-pricing-pressure-2292221.html
5. Aurobindo Pharma gains over 10% on positive growth outlook The stock had hit a high and low of Rs 568.25 and Rs 506 so far in today's trade. http://www.business-standard.com/article/markets/aurobindo-pharma-gains-over-10-on-positive-growth-outlook-117053000480_1.html

References

http://www.aurobindo.com

Top Authors

• Cherry Ann Baluyut
• Samer Hafez
• Jeysel Rio D. Cawaling
• View all authors

Verification history

• 2,381 days ago


• 2,636 days ago


• 2,680 days ago


• View all verifications